Cyclobutyl sulfones as notch sparing gamma secretase inhibitors
View Patent ↗The invention encompasses a novel class of cyclobutyl sulfone derivatives which inhibit the processing of APP by the putative γ-secretase while sparing Notch signaling pathway, and thus are useful in the treatment or prevention of Alzheimer's disease without the development of Notch inhibition mediated gastrointestinal issues. Pharmaceutical compositions and methods of use are also included.
1. A compound according to Formula I
or pharmaceutically acceptable salt thereof, wherein:
X 1 is selected from the group consisting of: F and CN;
X 2 is selected from the group consisting of: F, Cl and CN;
X 3 is selected from the group consisting of F, Br, Cl, CN, CF 3 , OCF 3 , C(O)—OCH 3 and S—CH 3 ;
X 4 is selected from the group consisting of H, F and Cl;
R 1 is selected from the group consisting of:
(a) H,
(b) CH 3 ,
(c) —(CH 2 ) n —OR 3 ;
(d) —(CH 2 ) n —C(O)—OR 4 and
(e) —SO 2 —CF 3 ;
R 2 is H or CH 3 when the compound of formula I is in the cis configuration, otherwise R 2 is H;
R 3 is a five- or six-membered non-aromatic heterocycle having one oxygen heteroatom;
R 4 is H or CH 3 ; and
n is 1 to 4.
2. The compound according to claim 1 of Formula Ia
or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 2 wherein:
X 1 is F and
X 4 is H.
4. The compound according to claim 3 wherein:
X 2 is F and
X 3 is Cl.
5. The compound according to claim 4 wherein R 2 is H.
6. The compound according to claim 5 wherein R 1 is —(CH 2 ) n —C(O)—OR 4 .
7. The compound according to claim 1 of Formula Ib
or a pharmaceutically acceptable salt thereof.
8. The compound according to claim 7 wherein:
X 1 and X 2 are F;
X 3 is Cl; and
X 4 is H.
9. A compound according to claim 1 selected from the following group:
or a pharmaceutically acceptable salt of any of the foregoing compounds.
10. A compound according to claim 9 which is
or a pharmaceutically acceptable salt thereof.
11. A compound according to claim 10 which is
12. A compound according to claim 10 which is
13. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
14. A method of treatment of a subject suffering or prone to a condition associated with the deposition of β-amyloid which comprises administering to that subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.